ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients
ROUND ROCK, Texas, June 3, 2021 /PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of allergies, announced today that it has acquired OTIPRIO® (ciprofloxacin otic suspension) from Otonomy, Inc. OTIPRIO is a prescription fluoroquinolone antibacterial approved to treat pediatric patients 6 months of age and older with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP), and to treat acute otitis externa (AOE), also known as swimmer's ear, in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus. The acquisition will strengthen ALK's expansion into ear, nose and throat (ENT) and pediatrics. In June 2020, ALK signed an exclusive agreement with Otonomy for the co-promotion of OTIPRIO, which included exclusive rights to market OTIPRIO for AOE to office-based health care professionals in the U.S.
"ALK is excited to expand our portfolio to offer more innovative solutions to healthcare providers, including ENTs, primary care physicians and pediatricians, as well as their patients," said Jorge Alderete, President, ALK, Inc. "OTIPRIO is a great fit with our existing portfolio and supports our business strategy to broaden our commercial footprint in the U.S. with novel first-in-class products that can help improve patient outcomes via physician provided in-office procedures. Additionally, ALK will also now offer our other allergy immunotherapy products and penicillin allergy testing to an expanded set of healthcare provider specialties."
OTIPRIO is a sterile, preservative-free, otic suspension of 6 percent ciprofloxacin administered as a single-dose by a healthcare professional. The thermosensitive suspension exists as a liquid at or below room temperature and gels when warmed.
For bilateral otitis media with effusion, OTIPRIO is administered during ear tube surgery as a single 0.1 mL (6 mg) intratympanic administration into each affected ear, following suctioning of the middle ear effusion. For AOE, OTIPRIO is administered as a single 0.2 mL (12 mg) administration to the external ear canal of each affected ear.
About Bilateral Otitis Media with Effusion in Tympanostomy Tube Placement
About Acute Otitis Externa
Important Safety Information for OTIPRIO
Contraindications: OTIPRIO is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO.
Warnings and Precautions - Potential for Microbial Overgrowth: OTIPRIO may result in overgrowth of nonsusceptible bacteria and fungi. If such infections occur, institute alternative therapy.
Adverse Reactions - Bilateral otitis media with effusion clinical trials: Adverse reactions (incidence at least 3%) with OTIPRIO vs sham were: nasopharyngitis (5% vs 4%), irritability (5% vs 3%), and rhinorrhea (3% vs 2%). Acute otitis externa clinical trial: Adverse reactions (incidence at least 2%) with OTIPRIO vs sham were: ear pruritus (2% vs 2%), headache (2% vs 1%), otitis media (2% vs 1%), and ear discomfort (2% vs 0%).
Use in Specific Populations - Pediatric Use: The safety and effectiveness of OTIPRIO in infants below six months of age have not been established for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement and acute otitis externa.
Full prescribing information can be found at www.OTIPRIO.com.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For further information, please contact:
View original content to download multimedia:http://www.prnewswire.com/news-releases/alk-acquires-otiprio-ciprofloxacin-otic-suspension-broadening-treatment-solutions-for-healthcare-providers-and-patients-301304711.html
SOURCE ALK, INC.
Company Codes: Copenhagen:ALKB, OTC-PINK:AKBLF